Hideki Takeda
Net worth: 868 227 $ as of 2026-06-29
Net worth: 868 227 $ as of 2026-06-29
Hideki Takeda is the founder of Scent Science International, Inc. He is currently an Independent Outside Director at Modalis Therapeutics Corp., a Representative Director at Medical Patent Research, Inc., an Outside Director at Ctex Co. Ltd., and a Director at Liid Pharmaceuticals, Inc. He received his undergraduate and graduate degrees from Osaka University.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
PRISM BioLab Co., Ltd.
PRISM BioLab Co., Ltd. BiotechnologyHealth Technology Provides drug discovery and development services using proprietary platform technology 2.53% | 2026-03-30 | 935,000 ( 2.53% ) | 828 429 $ | 2026-06-29 |
| 2025-12-30 | 196,000 ( 0.2% ) | 39 798 $ | 2026-06-29 |
| Companies | Position | Start |
|---|---|---|
| MODALIS THERAPEUTICS CORPORATION | Director/Board Member | 2015-12-31 |
Medical Patent Research, Inc. | Director/Board Member | 2008-12-31 |
Ctex Co. Ltd. | Director/Board Member | 2018-01-31 |
Scent Science International, Inc.
Scent Science International, Inc. Industrial ConglomeratesProducer Manufacturing Develops animal repellant | Founder | 2010-07-22 |
Liid Pharmaceuticals, Inc. | Director/Board Member | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 6 |
|---|---|
Osaka University
Osaka University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Scent Science International, Inc.
Scent Science International, Inc. Industrial ConglomeratesProducer Manufacturing Develops animal repellant | Producer Manufacturing |
Modalis Therapeutics Corp.
Modalis Therapeutics Corp. BiotechnologyHealth Technology Develops transformative therapeutics for diseases which are caused by malfunctioning of genes | Health Technology |
Medical Patent Research, Inc. | |
Ctex Co. Ltd. | |
Liid Pharmaceuticals, Inc. |
Select your edition
All financial news and data tailored to specific country editions